Erythrocyte Ghost Mediated Retinal Diagnosis

Overview

Instead of the usual procedure of injecting ICG dye directly into an arm vein, now the dye can be placed inside of RBCs. When a small volume of the RBC's with the dye is injected into a person's arm, the individual RBCs can be seen as they flow through the retinal blood vessels.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2016

Detailed Description

Capillary erythrocyte movement throughout the entire human macula can be observed routinely for periods up to 20 minutes by autologous re-injection of a small volume (about 1 mL) of indocyanine green (ICG)-loaded erythrocytes, making possible for the first time quantification of blood flow in individual capillaries, including abnormal structures like choroidal neovascularization (CNV), and it makes possible characterization of vasomotion in ocular vasculatures.

Interventions

  • Procedure: ICG loaded erythrocytes
    • For each subject, on the morning of the day angiography was scheduled, or no longer than 4 days prior to angiography, 9 ml of blood will be withdrawn from an antecubital vein. Using sterile procedures, erythrocyte ghosts produced from the blood will be loaded with ICG dye (for the diagnostic part of the study) or with ICG and one of several drugs (for the therapeutic part of the study) by the following procedure, which requires about 2 hours and yields approximately 1 ml of packed cells (80% Ht) that, after microscopic examination, are ready for autologous re-injection

Arms, Groups and Cohorts

  • Experimental: ICG loaded erythrocytes
    • Ability to directly visualize erythrocyte dynamics within the retinal and choroidal microcirculations would facilitate focused investigations into the relationships between vasomotion (i.e., pulsatile erythrocyte movement through capillaries) and oxygen distribution to localized tissue regions.

Clinical Trial Outcome Measures

Primary Measures

  • Capillary erythrocyte movement
    • Time Frame: 1 hour
    • To demonstrate in each subject eye the differences between erythrocyte movement through retinal and choroidal capillaries in normal fundus areas and their movement through abnormal areas associated with vascular disease

Secondary Measures

  • Retinal capillary movement
    • Time Frame: 1 hour
    • To demonstrate the relationship between the state of retinal vasomotion and retinal edema in the human eye. The primary focus will be on eyes with CNV associated with age-related macular degeneration (AMD) and eyes with diabetic retinopathy (DR).

Participating in This Clinical Trial

Inclusion Criteria

1. A male or female, of any race who is at least 40 years of age and has clinical signs of CNV or exudative manifestations of AMD, has clinical signs of DR, or clinical signs of retinal occlusive disease. 2. Patients with subfoveal, extrafoveal or juxtafoveal CNV, which is classic, minimally classic or occult and has dimensions less than 25.0 mm2 as measured on the sodium fluorescein angiogram (SFA). 3. Patient with recurrent CNV, where previous treatment never involved the foveal avascular zone (FAZ). 4. Analysis of highspeed ICGA must show one or more welldefined feeder vessel. 5. Patient must have best corrected visual acuity based on the ETDRS chart between 20/40 and 20/320 in the study eye. 6. Patient must be willing, be able to comply with the protocol and provide informed consent. Exclusion Criteria:

1. CNV secondary to any cause other than AMD or DR. 2. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions. 3. Patient participating in any other investigational drug study. 4. Patient with significant liver disease or uremia. 5. Patient with known adverse reaction to indocyanine green or iodine. 6. Patient is pregnant or nursing.

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Northwell Health
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Lawrence A Yannuzzi, MD, Principal Investigator, NSLIJ/MEETH

References

Flower RW. Experimental studies of indocyanine green dye-enhanced photocoagulation of choroidal neovascularization feeder vessels. Am J Ophthalmol. 2000 Apr;129(4):501-12. doi: 10.1016/s0002-9394(99)00411-0.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.